99 reports

  • TUBERCULOSIS, PNEUMONIA, MRSA, SEPSIS, GLOBAL, PIPELINES BY MOLECULAR TARGET, 2017
  • 4.2.2 MRSA

Acquired Antibiotic Resistance Genes: An Overview.

  • Anti-Infective
  • Antibiotic Resistance
  • Infectious Disease
  • Therapy
  • Deals & Alliance
  • JUN 05, 2015: TAXIS PHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING POTENTIAL VIABILITY OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE
  • APR 27, 2015: TAXIS PHARMACEUTICALS DEMONSTRATES CLINICAL POTENTIAL OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE

The molecules developed by companies in Preclinical stages are ## respectively.

  • Anti-Infective
  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • Rising government initiatives to combat antibiotic resistance
  • RISING GOVERNMENT INITIATIVES TO COMBAT ANTIBIOTIC RESISTANCE

One such trend is the rising government initiatives to combat antibiotic resistance.

  • Antibiotic Resistance
  • World
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • immense threat from antibiotic resistance posed on global public health.

IMPETIGO - PIPELINE BY LABORATORIES OJER PHARMA SL, H## 2018 TOYAMA CHEMICAL CO LTD Impetigo - Drug Profiles MUPIROCIN - DRUG PROFILE NICLOSAMIDE - DRUG PROFILE immense threat from antibiotic resistance posed on global public health.

  • Anti-Infective
  • Antibiotic Resistance
  • Dermatological Condition
  • Therapy
  • Foamix Ltd.
  • APR 12, 2017: OPGEN TO PRESENT ANTIBIOTIC RESISTANCE PREDICTION DATA AT 25TH EUROPEAN CONGRESS OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES (ECCMID)
  • EQUITY OFFERING

Each unit consists of either one share of common stock, par value USD##. ## per share, or one share of non-voting, convertible preferred stock, and one warrant to acquire ##. ## of one share of common stock.

  • Antibiotic Resistance
  • Healthcare
  • Medical Equipment
  • United States
  • OpGen, Inc.
  • ALGORITHM - BACTERIAL ANTIBIOTIC RESISTANCE
  • ALGORITHM - BACTERIAL ANTIBIOTIC RESISTANCE PRODUCT OVERVIEW

## Microbial Infections ## Staphylococcus Infection ## Enterovirus Infection ## Fungal Infections ## Gram Negative Bacterial Infection ## Antimicrobial Resistant Infections ## Indication No of Products OPGEN INC - PIPELINE ANALYSIS OVERVIEW BUS

  • Antibiotic Resistance
  • Healthcare
  • Hospital
  • United States
  • OpGen, Inc.
  • Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance
  • Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance

The molecules developed by companies in Phase I stages are ## respectively.

  • Anti-Infective
  • Antibiotic Resistance
  • United States
  • World
  • Product Initiative
  • Apr 06, 2017: Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing

Unyvero System is a hardware platform used for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run.

  • Antibiotic Resistance
  • Medical Device
  • Medical Equipment
  • United States
  • Curetis N.V.
  • EQUITY OFFERING
  • OPGEN RAISES USD10 MILLION IN PUBLIC OFFERING OF UNITS

GlobalData OpGen Inc reported one pharmaceuticals & healthcare deal worth $## million in YTD 2018.

  • Antibiotic Resistance
  • Healthcare
  • Pharmaceutical
  • United States
  • OpGen, Inc.
  • Nov 16, 2017: US FDA Grants Qualified Infectious Disease Product Designation for RECCE 327
  • Jan 18, 2017: Recce's lead compound reduces illness in mice infected by resistant E. coil bacteria

Antibiotic resistance has been called one of the biggest public health threats of our time.

  • Antibiotic Resistance
  • United States
  • World
  • Company
  • Product Initiative
  • ATLAS IO SYSTEM - BACTERIAL IDENTIFICATION AND ANTIBIOTIC RESISTANCE
  • ATLAS IO SYSTEM - BACTERIAL IDENTIFICATION AND ANTIBIOTIC RESISTANCE - PRODUCT STATUS

Luber has been appointed Chief Executive Officer effective ## October 2017.

  • Antibiotic Resistance
  • Diagnostics
  • United Kingdom
  • United States
  • World
  • Emergence of antibiotic resistance
  • MARKET CHALLENGES

You can easily book an appointment with one online.

  • Antibiotic Resistance
  • Danaher Corporation
  • Merck & Co., Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • ANTIBIOTIC RESISTANCE PANEL
  • ANTIBIOTIC RESISTANCE PANEL - PRODUCT DESCRIPTION

Notes Recent Development section covers news posted during last one year GlobalData considers regulatory approved (Approved and Issued) products as pipeline in case products are yet to launch in the market.

  • Antibiotic Resistance
  • Biotech Diagnostics
  • Diagnostics
  • Company
  • Product Initiative

The details ##.

  • Antibiotic Resistance
  • World
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Official Title

The prominent features of this report are - ##.

  • Antibiotic Resistance
  • Clinical Trial
  • Drug Development
  • World
  • Product Initiative
  • Official Title
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Antibiotic Resistance
  • Clinical Trial
  • Therapy
  • World
  • Merck & Co., Inc.
  • 8.4.5.4.2 Antimicrobial Resistance Testing Market Revenue and Forecast to 2027 (US$ Mn)
  • Antimicrobial Resistance Testing Market Revenue and Forecasts to 2027 (US$ Mn)

Figure ##. ##.

  • Antibiotic Resistance
  • World
  • Forecast
  • Market Size
  • Bruker Corporation
  • SMALL MOLECULES TO INHIBIT LETHAL FACTOR FOR ANTHRAX AND CYSTIC FIBROSIS - DRUG PROFILE
  • ANTHRAX - PIPELINE BY VENOMYX INC, H1 2020

Anthrax - Overview Anthrax - Therapeutics Development PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR ANTHRAX, H## 2020 NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR ANTHRAX, H## 2020 Phase III ## ## Phase II ## ## Phase I ## ## Preclinical ## ## Discovery ## ## Unknown ## ## Tot

  • Antibiotic Resistance
  • Therapy
  • United States
  • Company
  • Product Initiative

Tetraphase Pharmaceuticals Inc (Tetraphase) is a pharmaceutical company that discovers and develops antibiotic resistance medicines.

  • Antibiotic Resistance
  • Infectious Disease
  • Therapy
  • United States
  • Product Initiative

The molecules developed by Companies in Phase II, Phase I, IND/ CTA Filed and Preclinical stages are ##, ##, ## and ## respectively.

  • Antibiotic Resistance
  • Therapy
  • United States
  • World
  • Product Initiative

One unit refers to one POC analyzer.

  • Antibiotic Resistance
  • Clinical Trial
  • International University
  • United States
  • McKesson Corporation

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ## and ## respectively.

  • Anti-Infective
  • Antibiotic Resistance
  • United States
  • Product Initiative
  • Basilea Pharmaceutica Ltd.

The combined OASIS-## and OASIS-## analysis showed that antibiotic resistance was common, occurring in ##. ## percent of S. aureus solates identified at baseline with more than one-third identified as MDR.

  • Antibiotic Resistance
  • Sexually Transmitted Disease
  • Therapy
  • United States
  • Product Initiative

The combined OASIS-## and OASIS-## analysis showed that antibiotic resistance was common, occurring in ##. ## percent of S. aureus solates identified at baseline with more than one-third identified as MDR.

  • Antibiotic Resistance
  • Sexually Transmitted Disease
  • United States
  • Company
  • Product Initiative
  • SELECTED COMPANIES MARKETING PCR/NAAT-BASED ANTIBIOTIC RESISTANCE/SUSCEPTIBILITY TESTS
  • SELECTED COMPANIES MARKETING PCR/NAAT SYNDROMIC TESTS/PANELS FOR INFECTIOUS DISEASES

Some of these tests also detect one or more antibiotic resistance genes.

  • Antibiotic Resistance
  • Biotech Diagnostics
  • Blood Supply
  • Molecular Diagnostics
  • Biocartis S.A.
  • Official Title

The combined OASIS-## and OASIS-## analysis showed that antibiotic resistance was common, occurring in ##. ##% of S. aureus solates identified at baseline with more than one-third identified as MDR (=## antibiotic classes).

  • Anti-Infective
  • Antibiotic Resistance
  • Clinical Trial
  • World
  • Merck & Co., Inc.
  • 12.3.4 Antibiotic Resistance Patterns
  • ILLUSTRATION DEPICTING THE KEY MECHANISMS OF ANTIBIOTIC RESISTANCE OBSERVED IN GRAM-

THE ANTIBIOTIC RESISTANCE CRISIS PART ##: CAUSES AND THREATS.

  • Antibiotic Resistance
  • Achaogen, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • The Medicines Company

The combined OASIS-## and OASIS-## analysis showed that antibiotic resistance was common, occurring in ##. ## percent of S. aureus solates identified at baseline with more than one-third identified as MDR.

  • Antibiotic Resistance
  • Infectious Disease
  • Therapy
  • United States
  • Product Initiative

The combined OASIS-## and OASIS-## analysis showed that antibiotic resistance was common, occurring in ##. ## percent of S. aureus solates identified at baseline with more than one-third identified as MDR.

  • Anti-Infective
  • Antibiotic Resistance
  • Therapy
  • United States
  • Product Initiative
  • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Product Development Milestones

Announcement comes at a critical time for the antibiotic industry, in light of the latest report from the O' Neill Review on Antibiotic Resistance (##th May 2015), which highlighted the human and financial costs that society faces as a result of antibiotic resistant infections,

  • Antibiotic Resistance
  • Hospital
  • World
  • Product Initiative
  • MGB Biopharma Limited